ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Rating of “Moderate Buy” by Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $77.33.

A number of research firms have recently commented on ANIP. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Raymond James raised their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Finally, Piper Sandler initiated coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target on the stock.

Insider Activity

In related news, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 33,981 shares of company stock worth $1,970,066 over the last quarter. 12.70% of the stock is currently owned by corporate insiders.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Alpha Capital Management Ltd. boosted its position in shares of ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after buying an additional 9,500 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth $600,000. Susquehanna Fundamental Investments LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth $228,000. Boston Partners bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth $606,000. Finally, Thompson Siegel & Walmsley LLC raised its holdings in shares of ANI Pharmaceuticals by 17.6% in the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock valued at $13,731,000 after purchasing an additional 34,416 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Stock Down 3.6 %

Shares of ANIP opened at $57.23 on Monday. The stock’s 50-day moving average price is $58.22 and its two-hundred day moving average price is $60.64. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a market capitalization of $1.20 billion, a PE ratio of -104.05 and a beta of 0.71. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm’s revenue was up 12.5% compared to the same quarter last year. During the same period last year, the company earned $1.05 earnings per share. On average, analysts anticipate that ANI Pharmaceuticals will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.